Phase 1 N=2 Treatment

Ranibizumab Therapy for Non-arteritic Ischemic Optic Neuropathy

Nonarteritic Anterior Ischemic Optic Neuropathy

Bottom Line

View on ClinicalTrials.gov: NCT00561834 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Jul 2016

Primary outcome: Primary: Change in Visual Acuity — 4; 3 lines change in Snellen chart

Study Design & Population

Study type: Interventional
Phase: Phase 1
Interventions: ranibizumab (Drug)
Age: Adult, Older Adult · 21+ yrs
Sex: All
Sponsor: University of Colorado, Denver
Primary completion: Apr 2009

Outcome Measures

Outcome	Result	p-value
PRIMARY Change in Visual Acuity	4; 3	—

Summary

The purpose of this study is to explore the safety and efficacy of ranibizumab to treat non-arteritic ischemic optic neuropathy based on clinical and anatomical findings.

Eligibility Criteria

Inclusion Criteria

provide written informed consent
21 years of age or older
new onset, within 14 days, of ischemia and vision loss
Best Corrected Visual Acuity (BCVA) 20/40 or worse

Exclusion Criteria

pregnancy or lactation
proliferative diabetic retinopathy,
diabetic macular edema,
uveitis,
history of ocular trauma,
severe glaucoma,
age-related macular degeneration.
prior or concomitant treatment of oral steroids within 30 days,
participation in any studies of investigational drugs within 30 days,
participation in a ranibizumab clinical trial or,
prior treatment intravitreally or intravenously of Avastin or steroids.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00561834). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.